公开(公告)号：US20210024565A1

公开(公告)日：2021-01-28

申请号：US17061409

申请日：2020-10-01

申请人： Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

发明人： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo La Colla

IPC分类号： C07H19/16 ,  A61K47/60 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  A61K38/21 ,  A61K45/06 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/22 ,  A61K31/7068 ,  A61K31/708 ,  C07H19/056 ,  C07H19/06 ,  A61K31/7056 ,  A61K9/20 ,  A61K9/48

摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

公开(公告)号：US20180237467A1

公开(公告)日：2018-08-23

申请号：US15890990

申请日：2018-02-07

申请人： Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

发明人： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo La Colla

IPC分类号： C07H19/16 ,  A61K31/7056 ,  A61K45/06 ,  C07H19/06 ,  C07H19/056 ,  A61K38/21 ,  A61K31/708 ,  A61K31/7068 ,  A61K47/60 ,  A61K9/48 ,  A61K9/20 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  C07H19/22 ,  C07H19/048 ,  C07H19/04 ,  C07H19/00

CPC分类号： C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

公开(公告)号：US20130330297A1

公开(公告)日：2013-12-12

申请号：US13958463

申请日：2013-08-02

申请人： Idenix Pharmaceuticals, Inc. ,  L'Universite Montpellier II (UMII) ,  Centre National De La Recherche Scientifique (CNRS) ,  Universita degli Studi di Cagliari

发明人： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo LaColla

IPC分类号： A61K38/21 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  A61K31/7076

CPC分类号： C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

摘要翻译： 描述了1'，2'，3'或4'-支链核苷的2'和/或3'前药及其药学上可接受的盐和衍生物。 这些前药可用于预防和治疗黄病毒科感染，包括HCV感染和其他相关病症。 描述本发明前药的化合物和组合物。 还提供了包括施用有效量的本发明前药或其药学上可接受的盐或衍生物的方法和用途。 这些药物可以任选地与另外的抗病毒剂组合或改变来施用，以预防或治疗黄病毒科感染和其他相关病症。

公开(公告)号：US10513534B2

公开(公告)日：2019-12-24

申请号：US14047862

申请日：2013-10-07

申请人： IDENIX PHARMACEUTICALS LLC ,  Centre National De La Recherche Scientifique ,  UNIVERSITE DE MONTPELLIER

发明人： Gilles Gosselin ,  Christophe Claude Parsy ,  Francois-Rene Alexandre ,  Houcine Rahali ,  Jean-Francois Griffon ,  Dominique Surleraux ,  Cyril B. Dousson ,  Claire Pierra ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistair James Stewart

IPC分类号： C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  C07H19/11 ,  C07H19/16 ,  C07H19/173 ,  C07H19/20 ,  C07H19/213 ,  A61K31/7072 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7076 ,  C07H19/14 ,  A61K31/7064 ,  C07H19/12 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/403 ,  A61K31/497 ,  A61K31/7105 ,  C07H19/23

摘要： Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

公开(公告)号：US10238680B2

公开(公告)日：2019-03-26

申请号：US14954815

申请日：2015-11-30

申请人： IDENIX PHARMACEUTICALS LLC ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER

发明人： Benjamin Alexander Mayes ,  Adel M. Moussa ,  Cyril B. Dousson ,  Gilles Gosselin ,  Claire Pierra ,  David Dukhan

IPC分类号： C07H19/10 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  A61K9/00

摘要： Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.

公开(公告)号：US10231986B2

公开(公告)日：2019-03-19

申请号：US14866759

申请日：2015-09-25

申请人： Centre National De La Recherche Scientifique ,  Universite Montpellier 2 Sciences Et Techniques ,  Idenix Pharmaceuticals LLC

发明人： David Dukhan ,  Christophe Claude Parsy ,  Gilles Gosselin ,  Jean-François Griffon ,  Guillaume Brandt ,  Cyril B. Dousson ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistar James Stewart

IPC分类号： C07H19/073 ,  C07H19/10 ,  C07H19/173 ,  C07H19/20 ,  A61K31/7072 ,  C07H17/02 ,  A61K31/7068 ,  A61K45/06 ,  A61K9/00 ,  A61K31/7076

摘要： Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.

公开(公告)号：US20140113880A1

公开(公告)日：2014-04-24

申请号：US14146520

申请日：2014-01-02

申请人： Idenix Pharmaceuticals, Inc. ,  L'Universite Montpellier II ,  Centre National de la Recherche Scientiflque ,  Universita degli Studi di Cagliari

发明人： Richard Storer ,  Gilles Gosselin ,  Jean-Pierre Sommadossi ,  Paolo LaColla

IPC分类号： C07H19/16

CPC分类号： C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

摘要翻译： 描述了1'，2'，3'或4'-支化核苷的2'和/或3'前药及其药学上可接受的盐和衍生物。 这些前药可用于预防和治疗黄病毒科感染，包括HCV感染和其他相关病症。 描述本发明前药的化合物和组合物。 还提供了包括施用有效量的本发明前药或其药学上可接受的盐或衍生物的方法和用途。 这些药物可以任选地与另外的抗病毒剂组合或改变来施用，以预防或治疗黄病毒科感染和其他相关病症。

公开(公告)号：US09249173B2

公开(公告)日：2016-02-02

申请号：US14197078

申请日：2014-03-04

申请人： Idenix Pharmaceuticals, Inc. ,  Centre National de la Recherche Scientifique ,  Universite Montpellier II

发明人： Jean-Pierre Sommadossi ,  Gilles Gosselin ,  Claire Pierra ,  Christian Perigaud ,  Suzanne Peyrottes

IPC分类号： A61K31/70 ,  C07H17/02 ,  C07F9/6558 ,  C07F9/6561 ,  C07H19/00 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708

CPC分类号： C07H17/02 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  C07F9/65586 ,  C07F9/65616 ,  C07H19/00

摘要： Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

摘要翻译： 本文提供了用于治疗肝脏疾病（包括HCV和/或HBV感染）的化合物，组合物和方法。 具体地，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。

公开(公告)号：US09186369B2

公开(公告)日：2015-11-17

申请号：US14269003

申请日：2014-05-02

申请人： Idenix Pharmaceuticals, Inc. ,  The Centre National de la Recherche Scientifique ,  L'Universite Montpellier II

发明人： Richard Storer ,  Gilles Gosselin ,  David Dukhan ,  Frederic Leroy

IPC分类号： C07H19/23 ,  C07D487/04 ,  C07D405/04 ,  C07D409/04 ,  A61K31/7052 ,  A61K31/5025 ,  A61K31/53 ,  A61P31/14 ,  A61K31/706 ,  A61K31/00 ,  C07H19/044 ,  C07H19/052 ,  C07H19/056 ,  A61K45/06 ,  C07H19/04

CPC分类号： A61K31/706 ,  A61K31/00 ,  A61K45/06 ,  C07H19/04 ,  C07H19/044 ,  C07H19/052 ,  C07H19/056 ,  C07H19/23

摘要： This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

摘要翻译： 本发明涉及用于治疗感染丙型肝炎，黄病毒和/或瘟病毒的宿主，特别是人的方法，包括向该宿主施用有效量的抗HCV生物活性戊呋喃核苷，其中戊呋喃核苷碱基是任选的 取代的2-氮杂嘌呤。 任选取代的五氟鸟苷或其盐或前药可以单独施用或与一种或多种任选取代的五氟鸟苷或其它抗病毒剂组合施用。

公开(公告)号：US09309275B2

公开(公告)日：2016-04-12

申请号：US14195388

申请日：2014-03-03

申请人： Idenix Pharmaceuticals, Inc. ,  Centre National De La Recherche Scientifique ,  Universite Montpellier 2 Sciences Et Techniques

发明人： Alistair James Stewart ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Francois-Rene Alexandre ,  Dominique Surleraux ,  Christophe Claude Parsy ,  Claire Pierra ,  David Dukhan ,  Gilles Gosselin

IPC分类号： C07H19/044 ,  C07H19/06 ,  C07H19/10 ,  C07H19/14 ,  C07H19/16 ,  C07H19/20 ,  C07H19/207 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/7076 ,  A61K31/7072 ,  A61K45/06 ,  A61K31/40 ,  A61K31/497 ,  A61K31/7056 ,  A61K38/21

CPC分类号： C07H19/207 ,  A61K31/40 ,  A61K31/497 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/212 ,  A61K45/06 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  A61K2300/00

摘要： Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.

摘要翻译： 本文提供了用于治疗黄病毒科感染（包括HCV感染）的化合物，组合物和方法。 在某些实施方案中，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。 在某些实施方案中，化合物是根据式3001a或3001b的3'-脱氧核苷化合物：或其药学上可接受的盐，溶剂合物，立体异构形式，互变异构形式或其多晶型，其中PD，碱基和碱基2如本文所提供。